FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

W	as	hir	igton	, D.	C.	205	549
---	----	-----	-------	------	----	-----	-----

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
3235-0287								
Estimated average burden								
: 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Lyon Joseph Douglas (Last) (First) (Middle) C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE (Street) MENLO PARK CA 94025				2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC CORT 3. Date of Earliest Transaction (Month/Day/Year) 03/01/2023 4. If Amendment, Date of Original Filed (Month/Day/Year)								ORT (S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below)					oplicable	
(City)	(St	rate) (2	Zip)																
		Table	I - No	on-Deriva	tive	Secui	rities	Acc	uired	I, Dis	sposed of	, or B	enefic	ially	Own	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/				(Year) Execution		eemed tion Date, h/Day/Year)		3. Transaction Code (Instr. 8) 4. Securities A Disposed Of (D					and 5) Securi Benefi Owned		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price			ection(s) 3 and 4)			(Instr. 4)
Common Stock 03/01/20)23			Α		1,155(1)	Α	\$19.	9.86(2)		1,155		D			
Common Stock 03/01/20				023				A		1,155(3)	A	\$0.	00	2	2,310		D		
		Tal	ble II								oosed of, convertib				Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu	eemed ution Date, :h/Day/Year)	4. Transaction Code (Instr. 8)		5. Num of Derive Secur Acqui (A) or Dispo of (D) (Instr.	ative rities ired osed	6. Date Expira (Monti	tion D		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		Der Sec (Ins	Price of erivative ecurity nstr. 5) Proceed Following Reported Transactic (Instr. 4)		y O Fo O (I)	0. Iwnership orm: irect (D) r Indirect) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2023

(D)

Date Exercisable

Expiration Date

- 2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
- 3. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the oneyear anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

/s/ Joseph Douglas Lyon 03/03/2023

** Signature of Reporting Person Date

Number

Shares

Title

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.